Evidence of Use of Whole-Body Vibration in Individuals with Metabolic Syndrome: A Systematic Review and Meta-Analysis.

Abstract

(1) Background: Metabolic syndrome (MSy) is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increase the risk of cardiovascular disease. This systematic review with meta-analysis was conducted to assess the effects of whole-body vibration exercise (WBVE) in metabolic syndrome (MSy) individuals. (2) Methods: An electronic search in Pubmed, Embase, Scopus, Web of Science, ScienceDirect, PEDro, and CINAHL databases in December 2022 was performed. Data regarding the included studies were extracted. The level of evidence, the methodological quality, and the risk of bias of each selected publication were individually evaluated. (3) Results: Eight studies were included in the systematic review and four studies in the meta-analysis, with a mean methodological quality score on the Physiotherapy Evidence Database (PEDro scale) of 5.6, considered ‘fair’ quality. The qualitative results suggested positive effects of the systemic vibration therapy in relevant outcomes, such as quality of life, functionality, pain level, trunk flexibility, cardiovascular responses (blood pressure and heart rate), neuromuscular activation, range of motion of the knees, rating of perceived exertion, and body composition. The quantitative results, with weighted mean differences, standard mean differences, and 95% confidence intervals (CIs), were calculated. Conclusions: WBVE may be an alternative capable of interfering with physical-mainly for flexibility with weighted mean differences (1.70; 95% CI 0.15, 3.25; n = 39)-functional, psychosocial, neuromuscular, emotional parameters, and consequently contribute to improvements in metabolic health and reduce the cardiovascular risk factor in MSy individuals. Nevertheless, further additional studies are required to understand the long-term effects of WBVE on MSy and its complications in a better way. Protocol study registration was as follows: PROSPERO (CRD 42020187319).

Autor: Coelho-Oliveira AC, Monteiro-Oliveira BB, Goncalves de Oliveira R, Reis-Silva A, Ferreira-Souza LF, Lacerda ACR, Mendonca VA, Sartorio A, Taiar R, Bernardo-Filho M, Sa-Caputo D

Organisation: Programa de Pos-Graduacao em Fisiopatologia Clinica e Experimental, Universidade do Estado do Rio de Janeiro, Rio de Janeiro 20551-030, RJ, Brazil.

Jahr: 2023

GID: 5923

Erstellt am: 28.02.2023

Das Urteil unserer Kunden: Hervorragend

4.7/5

4,7 von 5 Sternen basierend auf 868 Bewertungen

TÜV zertifiziert

Wir sind vom TÜV zertifizierter Hersteller für Medizinprodukte.

Made in Germany

Die Entwicklung und Herstellung findet nur in Deutschland statt.

Bewährte Qualität

10 Jahre Servicegarantie & mehr als 35 Jahre Erfahrung im Firmenverbund.

Studien

Über 2000 wissenschaftliche Publikationen zu unseren Produkten.

Weltweit Tätig

Mit unseren Vertriebspartnern international tätig.

Fangen Sie an zu tippen, um die gesuchten Beiträge zu sehen.